Quick Answer
Minerva Neurosciences, Inc. reported Cash and Equivalents of $82.30 million for fiscal year 2025.
Minerva Neurosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $82.30M | +285.3% |
| 2024 | $21.36M | -47.8% |
| 2023 | $40.91M | +13.4% |
| 2022 | $36.09M | -40.6% |
| 2021 | $60.76M | +139.6% |
| 2020 | $25.36M | +18.4% |
| 2019 | $21.41M | -57.4% |
| 2018 | $50.23M | +92.8% |
| 2017 | $26.05M | -68.6% |
| 2016 | $82.98M | +480.9% |
| 2015 | $14.28M | -23.0% |
| 2014 | $18.55M | +919.9% |
| 2013 | $1.82M | +807.7% |
| 2012 | $200.3K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.29M | -53.7% | -19.4% |
| June 30, 2025 | $15.25M | -50.6% | -11.8% |
| March 31, 2025 | $17.29M | -50.3% | -19.1% |
| December 31, 2024 | $21.36M | -47.8% | -19.5% |
| September 30, 2024 | $26.53M | -43.4% | -14.1% |
| June 30, 2024 | $30.88M | -40.4% | -11.3% |
| March 31, 2024 | $34.82M | -3.2% | -14.9% |
| December 31, 2023 | $40.91M | +13.4% | -12.8% |
- Minerva Neurosciences, Inc. showed an increase of +285.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Minerva Neurosciences, Inc.’s cash and equivalents has grown by 40986.4% (from $200.3 thousand to $82.30 million).
- The most recent figure is from Minerva Neurosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: